Key clinical point: Lenalidomide maintenance after chemoimmunotherapy prolongs progression- and event-free survival, but is associated with the potential risk for B-cell acute lymphoblastic leukemia (B-ALL).
Major finding: Three cases of ALL occurred in the lenalidomide maintenance arm.
Study details: 4-year follow-up of the phase 3 CLLM1 study of 89 patients.
Disclosures: The CLLM1 study was funded by Celgene.
Furstenau M et al. iwCLL 2019, Abstract 2017.